Skip to main content
PMC home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1997 Jan 1;25(1):151–157. doi: 10.1093/nar/25.1.151

Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects.

P Hainaut 1, T Soussi 1, B Shomer 1, M Hollstein 1, M Greenblatt 1, E Hovig 1, C C Harris 1, R Montesano 1
PMCID: PMC146396  PMID: 9016527

Abstract

In recent years, there has been an exponential increase in the number of p53 mutations identified in human cancers. The p53 mutation database consists of a list of point mutations in thep53 gene of human tumors and cell lines, compiled from the published literature and made available through electronic media. The database is now maintained at the International Agency for Research on Cancer (IARC) and is updated twice a year. The current version contains records on 5091 published mutations and is expected to surpass the 6000 mark in the January 1997 release. The database is available in various formats through the European Bioinformatics Institute (EBI) ftp server at: ftp://ftp.ebi.ac.uk/pub/databases/p53/ or by request from IARC (p53database@iarc.fr) and will be searchable through the SRS system in the near future. This report provides a description of the criteria for inclusion of data and of the current formats, a summary of the relevance ofp53 mutation analysis to clinical and biological questions, and a brief discussion of the prospects for future developments.

Full Text

The Full Text of this article is available as a PDF (169.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguilar F., Hussain S. P., Cerutti P. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8586–8590. doi: 10.1073/pnas.90.18.8586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartsch H., Hollstein M., Mustonen R., Schmidt J., Spiethoff A., Wesch H., Wiethege T., Müller K. M. Screening for putative radon-specific p53 mutation hotspot in German uranium miners. Lancet. 1995 Jul 8;346(8967):121–121. doi: 10.1016/s0140-6736(95)92144-3. [DOI] [PubMed] [Google Scholar]
  3. Biggs P. J., Warren W., Venitt S., Stratton M. R. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. Mutagenesis. 1993 Jul;8(4):275–283. doi: 10.1093/mutage/8.4.275. [DOI] [PubMed] [Google Scholar]
  4. Cariello N. F., Douglas G. R., Soussi T. Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents. Nucleic Acids Res. 1996 Jan 1;24(1):119–120. doi: 10.1093/nar/24.1.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cho Y., Gorina S., Jeffrey P. D., Pavletich N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994 Jul 15;265(5170):346–355. doi: 10.1126/science.8023157. [DOI] [PubMed] [Google Scholar]
  6. Etzold T., Argos P. SRS--an indexing and retrieval tool for flat file data libraries. Comput Appl Biosci. 1993 Feb;9(1):49–57. doi: 10.1093/bioinformatics/9.1.49. [DOI] [PubMed] [Google Scholar]
  7. Forrester K., Lupold S. E., Ott V. L., Chay C. H., Band V., Wang X. W., Harris C. C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene. 1995 Jun 1;10(11):2103–2111. [PubMed] [Google Scholar]
  8. Gailani M. R., Leffell D. J., Ziegler A., Gross E. G., Brash D. E., Bale A. E. Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. J Natl Cancer Inst. 1996 Mar 20;88(6):349–354. doi: 10.1093/jnci/88.6.349. [DOI] [PubMed] [Google Scholar]
  9. Goh H. S., Yao J., Smith D. R. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 1995 Nov 15;55(22):5217–5221. [PubMed] [Google Scholar]
  10. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  11. Greenblatt M. S., Grollman A. P., Harris C. C. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res. 1996 May 1;56(9):2130–2136. [PubMed] [Google Scholar]
  12. Harris C. C. The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer. 1996 Feb;73(3):261–269. doi: 10.1038/bjc.1996.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hartmann A., Blaszyk H., Saitoh S., Tsushima K., Tamura Y., Cunningham J. M., McGovern R. M., Schroeder J. J., Sommer S. S., Kovach J. S. High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br J Cancer. 1996 Apr;73(8):896–901. doi: 10.1038/bjc.1996.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hartmann A., Rosanelli G., Blaszyk H., Cunningham J. M., McGovern R. M., Schroeder J. J., Schaid D. J., Kovach J. S., Sommer S. S. Novel pattern of P53 mutation in breast cancers from Austrian women. J Clin Invest. 1995 Feb;95(2):686–689. doi: 10.1172/JCI117714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hollstein M., Shomer B., Greenblatt M., Soussi T., Hovig E., Montesano R., Harris C. C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res. 1996 Jan 1;24(1):141–146. doi: 10.1093/nar/24.1.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ko L. J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996 May 1;10(9):1054–1072. doi: 10.1101/gad.10.9.1054. [DOI] [PubMed] [Google Scholar]
  17. Krawczak M., Smith-Sorensen B., Schmidtke J., Kakkar V. V., Cooper D. N., Hovig E. Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Hum Mutat. 1995;5(1):48–57. doi: 10.1002/humu.1380050107. [DOI] [PubMed] [Google Scholar]
  18. Nataraj A. J., Black H. S., Ananthaswamy H. N. Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7961–7965. doi: 10.1073/pnas.93.15.7961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ory K., Legros Y., Auguin C., Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 1994 Aug 1;13(15):3496–3504. doi: 10.1002/j.1460-2075.1994.tb06656.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rolley N., Butcher S., Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene. 1995 Aug 17;11(4):763–770. [PubMed] [Google Scholar]
  21. Saitoh S., Cunningham J., De Vries E. M., McGovern R. M., Schroeder J. J., Hartmann A., Blaszyk H., Wold L. E., Schaid D., Sommer S. S. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene. 1994 Oct;9(10):2869–2875. [PubMed] [Google Scholar]
  22. Soini Y., Welsh J. A., Ishak K. G., Bennett W. P. p53 mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. Carcinogenesis. 1995 Nov;16(11):2879–2881. doi: 10.1093/carcin/16.11.2879. [DOI] [PubMed] [Google Scholar]
  23. Sommer S. S., Cunningham J., McGovern R. M., Saitoh S., Schroeder J. J., Wold L. E., Kovach J. S. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. J Natl Cancer Inst. 1992 Feb 19;84(4):246–252. doi: 10.1093/jnci/84.4.246. [DOI] [PubMed] [Google Scholar]
  24. Soussi T. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today. 1996 Aug;17(8):354–356. doi: 10.1016/0167-5699(96)30019-4. [DOI] [PubMed] [Google Scholar]
  25. Soussi T. The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Mol Med Today. 1996 Jan;2(1):32–37. doi: 10.1016/1357-4310(96)88756-9. [DOI] [PubMed] [Google Scholar]
  26. Taylor J. A., Watson M. A., Devereux T. R., Michels R. Y., Saccomanno G., Anderson M. p53 mutation hotspot in radon-associated lung cancer. Lancet. 1994 Jan 8;343(8889):86–87. [PubMed] [Google Scholar]
  27. Vähäkangas K. H., Samet J. M., Metcalf R. A., Welsh J. A., Bennett W. P., Lane D. P., Harris C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992 Mar 7;339(8793):576–580. doi: 10.1016/0140-6736(92)90866-2. [DOI] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES